Top-News
Quelle: - © AdrianHancu / iStock Editorial / Getty Images Plus / Getty Images:
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between August 10, 2023 and June 25, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before October 6, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Altimmune touted the performance of its drug candidate Pemvidutide ahead of the results from its IMPACT Phase 2B MASH trial ("the trial"). When the results of the trial were released, they showed that Pemvidutide failed to achieved a statistically significant result in its primary endpoint. The Company treated this failure indifferently, claiming it expected a better result from its Phase 3 trial. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Altimmune, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
View original content to download multimedia:https://www.prnewswire.com/news-releases/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302560095.html
SOURCE The Schall Law Firm
Für dich aus unserer Redaktion zusammengestellt
Dein Kommentar zum Artikel im Forum
Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.